{
    "name": "brincidofovir",
    "comment": "Rx",
    "other_names": [
        "Tembexa"
    ],
    "classes": [
        "Antivirals",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/tembexa-brincidofovir-4000173",
    "pregnancy": {
        "common": [
            "Based on findings from animal reproduction studies, may cause fetal harm when administered to pregnant females",
            "Perform pregnancy testing in individuals of childbearing potential before initiating"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Administration to pregnant rats and rabbits during organogenesis resulted in embryotoxicity and structural malformations",
                    "These effects occurred in animals at systemic exposures less than the expected human exposure based on the recommended dose"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of childbearing potential: Use effective contraception during treatment and for at least 2 months after the last dose",
                    "Males: Advise sexually active individuals with partners of childbearing potential to use condoms during treatment and for at least 4 months after last dose"
                ]
            },
            {
                "type": "Male infertility",
                "description": [
                    "Based on testicular toxicity in animal studies, may irreversibly impair fertility in males of reproductive potential"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Administration to pregnant rats and rabbits during organogenesis resulted in embryotoxicity and structural malformations",
                    "These effects occurred in animals at systemic exposures less than the expected human exposure based on the recommended dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Increased incidence of mortality observed in brincidofovir-treated individuals compared with placebo-treated individuals in a 24-week clinical trial when evaluated in another disease"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Increased mortality if used for longer duration",
                    "description": [
                        "Not indicated for use in diseases other than human smallpox",
                        "Increased mortality observed in a randomized, placebo-controlled phase 3 trial when evaluated for another disease (CMV infection)",
                        "Increased risk in mortality is possible if used for a duration longer than at the recommended dosage on Days 1 and 8"
                    ]
                },
                {
                    "type": "Elevated hepatic transaminases and bilirubin",
                    "description": [
                        "Elevations in ALT, AST, and total bilirubin observed",
                        "Perform hepatic laboratory testing in all patients before starting and during treatment, as clinically appropriate",
                        "Monitor patients who develop abnormal test results for development of severe hepatic injury",
                        "Consider discontinuing if ALT levels remain persistently >10x ULN",
                        "Do not give second dose if ALT elevation accompanied by clinical signs and symptoms of liver inflammation or increasing direct bilirubin, alkaline phosphatase, or INR"
                    ]
                },
                {
                    "type": "Diarrhea and GI adverse effects",
                    "description": [
                        "Diarrhea common during treatment",
                        "Other GI effects include nausea, vomiting, and abdominal pain",
                        "Monitor for dehydration, and if necessary, do not give the second dose"
                    ]
                },
                {
                    "type": "Embryofetal toxicity, carcinogenicity, and male infertility",
                    "description": [
                        "Based on findings from animal reproduction studies, may cause fetal harm when administered to pregnant females",
                        "Considered a potential human carcinogen; mammary adenocarcinomas and squamous cell carcinomas occurred in rats at systemic exposures less than the expected human exposure based on the recommended dose",
                        "Based on testicular toxicity in animal studies, may irreversibly impair fertility in males of reproductive potential"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Cidofovir",
                        "Do not coadminister with IV cidofovir",
                        "Brincidofovir, a lipid-linked derivative of cidofovir, is intracellularly converted to cidofovir",
                        "OATP 1B1 and 1B3 inhibitors",
                        "If possible, consider alternant medications that are not OATP1B1 or 1B3 inhibitors",
                        "If concomitant use is necessary, increase monitoring for adverse reactions associated with brincidofovir (elevations in transaminases and bilirubin, diarrhea, or other GI adverse events) and postpone dosing of OATP1B1 or 1B3 inhibitors for at least 3 hr after brincidofovir administration",
                        "Vaccines ",
                        "No vaccine-drug interaction studies have been performed in humans; clinical impacts unknown",
                        "Animal studies suggest coadministration of brincidofovir at the same time as live smallpox vaccine (vaccinia virus) may reduce the immune response to the vaccine",
                        "Brincidofovir may reduce immune response to replication-defective smallpox vaccine (modified vaccinia virus Ankara)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of brincidofovir by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "General and administration site",
            "percent": null
        },
        {
            "name": "Peripheral edema",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue",
            "percent": null
        },
        {
            "name": "Muscular weakness",
            "percent": null
        },
        {
            "name": "Nervous system",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "ie",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "maculopapular rash",
            "percent": null
        },
        {
            "name": "pruritic rash",
            "percent": null
        }
    ]
}